Cambridge Investment Research Advisors, Inc. Intellia Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 10,397 shares of NTLA stock, worth $107,297. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,397Holding current value
$107,297% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding NTLA
# of Institutions
315Shares Held
90.6MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$126 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$99.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$99 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$53.1 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$51.1 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $784M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...